Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2008;94:685-687; doi:10.1136/hrt.2007.135194
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

EDITORIALS

Should we monitor platelet function during antiplatelet therapy?

Paul Hjemdahl

Correspondence to:
Professor P Hjemdahl, Karolinska Institutet, Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), SE-171 76 Stockholm, Sweden; Paul.Hjemdahl@ki.se

The first 150 words of the full text of this article appear below.

Antiplatelet drug treatment is a cornerstone in cardiovascular prevention. Low-dose aspirin (ASA) inhibits platelet-dependent, cyclo-oxygenase-1 (COX-1)-mediated thromboxane formation from arachidonic acid (AA), and is usually the preferred drug.1 Clopidogrel inhibits platelet ADP (P2Y12) receptors, and is an alternative for patients who cannot take ASA or for co-treatment when dual antiplatelet therapy is needed.2 Benefits of treatment do not outweigh the increased risk of bleeding in primary prevention in low-risk patients. For high-risk coronary patients the benefits may be so large that dual (or even triple) antiplatelet drug therapy is indicated during limited periods of time with very high risk.

Aspirin and clopidogrel "resistance" are much discussed and there are several reviews on the subject (eg, Patrono and Rocca,3 Gurbel and Tantry,4 Cattaneo5). There is, however, still some confusion about how to diagnose and handle antiplatelet drug "resistance", and what high "residual platelet activity" in a treated patient actually means. . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
T Geisler, M Kapp, K Göhring-Frischholz, K Daub, C Dösch, B Bigalke, H Langer, C Herdeg, and M Gawaz
Heart 2008 94: 743-747. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Hjemdahl, P. (2009). Aspirin resistance testing not ready for "prime time". Heart 95: 1220-1222 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.